News

The combined company will have four products in its pipeline. AlgoRx’s portfolio of pain management drug candidates includes ALGRX 3268, which is in phase III clinical trials, ALGRX

Cubicin was originally approved in September, 2003, at 4 mg/kg intravenously once daily for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive organisms,

The 12-patient trial is the world’s first study to use a viral vector for the treatment of an adult neurological disease. The vector was injected into a specific

In the study, performed by Dr Yvonne Paterson, scientific founder of Advaxis, Listeria vaccine treatment was found to be significantly more effective than comparable DNA vaccines, even though

The $9 million follow-on investment is on top of the original founders’ commitment of approximately $14 million, which also included Hadasit, Star Ventures, and the Jerusalem Development Authority,

The company also expects to commence dosing patients with mild to moderate Alzheimer’s disease in a Phase 2a clinical trial in the next several weeks. “This study has

These partnerships will leverage Quidel’s global capabilities to collaborate with osteoporosis research institutions for the development of new markers which may benefit osteoporosis and post-menopausal patients. “With these

PG Biotech is a leading manufacturer of polymerase chain reaction (PCR)-based molecular diagnostic kits in China. Qiagen hopes the acquisition will expand its position as a provider of

Transplantation of insulin-producing pancreatic beta-cells shows great promise as a treatment for type 1 diabetes, but development of this therapy has been hampered by a severe shortage of